2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 353-355
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Biological Processes, Immune Mechanism, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

1057 Rebuilding the immune system: A single-cell atlas decoding post-transplant immunity

Maxim Isaac Maron, MD, PhD, Rachel Lorenc, BS2, Kenyon Weis3, Zoe Katsamakis4, Charlotte Wishnack5, Chloe Park6, Maria Adriana Cuibus7, Hussen Mohammed Ibrahim8, Roshan Sharma, PhD9, M Kazim Panjwani, PhD10, Aya Halawi11, Kimon Argyropoulos, MD, PhD12, Joshua A Fein, MD13, Katharine Hsu, MD, PhD14, Alan Hanash, MD, PhD15, Marcelo Pasquini, MD16, Ronan Chaligne, PhD17, Andri Leo Leo Lemarquis, MD,PhD18, Omar Abdel-Wahab, MD19, Leo Luznik, MD20, Miguel-Angel Perales, MD21, Susan DeWolf, MD22
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Weill Cornell Medicine, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Weill Cornell Medicine, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Weill Cornell Medical College, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Cleveland Clinic, Cleveland, Ohio, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Karolinska Institute, Stockholm, Sweden
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Successful immune reconstitution (IR) after allogeneic hematopoietic cell transplantation (allo-HCT) is essential for prevention of infection and relapse. How individual immunosuppressive strategies required to prevent graft-versus-host disease (GVHD) impact the longitudinal kinetics of recovery in relation to the risk of infection, relapse, and GVHD, remains unknown. To address this question, we leveraged longitudinal samples from the BMT CTN 1301 randomized multi-center study that compared three GVHD-prophylaxis strategies—tacrolimus/methotrexate (Tac/MTX), post-transplant cyclophosphamide (PT-Cy), and CD34-selection—in patients undergoing myeloablative HLA-matched allo-HCT for leukemia.

Here we present a multi-modal single-cell platform incorporating transcriptomic, cell-surface proteomic, T cell receptor (TCR) repertoire, and chimerism analysis to interrogate IR in patients with favorable transplant outcomes. We found delayed naive T cell reconstitution in PT-Cy and CD34-selection until one year post-transplant, offering protection from chronic GVHD at the expense of increased infection risk. For graft-versus-leukemia, we identified robust early recovery of NK cells in CD34-selection versus donor memory CD8 T cells in Tac/MTX and PT-Cy; effector CD8s in PT-Cy were oligoclonal with a potent cytotoxic profile. Although the proportions of lymphocyte subsets differed across study arms, their transcriptional programs aligned with those of healthy controls. Together, this work lays the foundation to understand how relapse and GVHD perturb IR as well as to identify strategies to promote post-transplant tolerance.

To study IR, we analyzed longitudinal post-transplant samples (days 35, 100, 180, 365) from sex-mismatched allo-HCT recipients without relapse or >grade 2 GVHD using spectral flow cytometry and tri-modality single-cell sequencing (TCR/RNA/CITE; n = 434,568 cells, 60 samples, 15 patients). Patients in the Tac/MTX and PT-Cy arms received marrow grafts; CD34-selected grafts were PBSC-derived. We annotated the phenotype, repertoire (αβ and γδ), and chimerism of 337,892 T/NK cells.

Naive T cells were delayed after PT-Cy (~1% until day 365, then 10%) and CD34-selection (<1% until day 365, then 4%) compared to Tac/MTX, which reached ~20% by day 35 and remained stable (p = 2.8e-09). Naive T cells were donor-derived in PT-Cy and CD34-selection, suggesting a post-thymic origin. While this delay in naive T cell recovery likely increased vulnerability to infection and therapy-related mortality, it may also prevent chronic GVHD. Regulatory T cells at day 35 were relatively spared in PT-Cy; however, their recovery was subsequently delayed. Given that relapse rates did not differ across study arms, we investigated IR of cytotoxic lymphocytes. With respect to innate lymphocytes, donor NK cells dominated early after CD34-selection, comprising 92% of lymphocytes, versus 6% at day 35 with PT-Cy, rising to ~15% by days 180 and 365; in Tac/MTX, NK cells represented ~30% of lymphocytes at days 35 and 100 with a decrease to ~20% at days 180 and 365 (p ≤ 2.4e-03 at all timepoints). γδ T cells were nearly absent after PT-Cy or CD34-selection throughout the first year, but comprised approximately 3% of lymphocytes with Tac/MTX (p ≤ 3.2e-03 through day 180; p = 0.054 at day 365). PT-Cy promoted a rapid and sustained expansion of oligoclonal, donor-derived CD8 effectors with a potent cytotoxicity signature including elevated ZNF683/HOBIT. CD8 effectors comprised ~30% of lymphocytes by day 35 and 50% by day 180, versus only 10% (day 35) and 25% (day 180) with Tac/MTX and 15-20% with CD34-selection (p ≤ 1.9e-02 at all timepoints). CD8 effectors in CD34-selection represented persistent host CD8 T cells.

To benchmark post-HCT IR against immunity in healthy individuals, we applied SCimilarity, a model for finding transcriptionally similar cells across millions of profiles. This analysis revealed that the reconstituting T/NK cells in our cohort are transcriptionally similar to their counterparts in a reference model trained on ~40 million cells. This emphasizes quantitative compositional differences rather than phenotypic aberrations in post-HCT immunity.

This study presents a single-cell atlas of lymphocyte IR across immunosuppressive strategies and links the cellular profile of IR to critical transplant outcomes. With this, we are poised to test the effect of adverse transplant events on IR and identify strategies to augment immune function.

Maxim Isaac Maron, MD, PhD: No relevant conflicts of interest to declare.